Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | TP53 | P04637 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13596393 | 0.77 | NPC1 (0.56) | NPC1TP53RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL20982659 | 0.76 | NPC1 (0.85) | NPC1TP53RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL9304583 | 0.75 | NPC1 (0.58) | NPC1TP53RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL28500114 | 0.74 | NPC1 (0.56) | NPC1TP53RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL13596384 | 0.74 | KDR (0.48) | NPC1TP53RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL13596386 | 0.74 | KDR (0.48) | NPC1TP53RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL13596389 | 0.74 | KDR (0.68) | NPC1TP53RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4781712 | 0.74 | KDR (0.68) | NPC1TP53RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL13596385 | 0.74 | KDR (0.68) | NPC1TP53RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL3125413 | 0.74 | NPC1 (0.75) | NPC1TP53RAB9AHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638518-B2 | Substituted pyrazole kinase inhibitors | JANSSEN PHARMACEUTICA (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7638518-B2 | Substituted pyrazole kinase inhibitors | JANSSEN PHARMACEUTICA (BE) | 2009-12-29 | — | — | US | disclosed |
| US-7638518-B2 | Substituted pyrazole kinase inhibitors | JANSSEN PHARMACEUTICA (BE) | 2009-12-29 | — | — | US | disclosed |
| US-20080153844-A1 | 3-(Benzimidazol-2-yl)pyrazole derivatives; inhibitors of ATP and protein kinase interactions; diabetes, rheumatoid arthritis, Crohn's disease, septic shock, cachexia, pancreatitis, Alzheimer's disease, Parkinson's disease; antimetastasis, anticarcinogenic, antitumor, antidepressant, antiallergen agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153844-A1 | 3-(Benzimidazol-2-yl)pyrazole derivatives; inhibitors of ATP and protein kinase interactions; diabetes, rheumatoid arthritis, Crohn's disease, septic shock, cachexia, pancreatitis, Alzheimer's disease, Parkinson's disease; antimetastasis, anticarcinogenic, antitumor, antidepressant, antiallergen agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153844-A1 | 3-(Benzimidazol-2-yl)pyrazole derivatives; inhibitors of ATP and protein kinase interactions; diabetes, rheumatoid arthritis, Crohn's disease, septic shock, cachexia, pancreatitis, Alzheimer's disease, Parkinson's disease; antimetastasis, anticarcinogenic, antitumor, antidepressant, antiallergen agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-26 | — | — | US | disclosed |
| WO-2008048502-A1 | SUBSTITUTED PYRAZOLE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153844-A1 | 3-(Benzimidazol-2-yl)pyrazole derivatives; inhibitors of ATP and protein kinase interactions; diabetes, rheumatoid arthritis, Crohn's disease, septic shock, cachexia, pancreatitis, Alzheimer's disease, Parkinson's disease; antimetastasis, anticarcinogenic, antitumor, antidepressant, antiallergen agents | ADK, ATP5ME, ATP5MK | NPC1 4476/4885TP53 971/4885RAB9A 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.